GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a health official said on Friday during a press briefing.

EST: Adds comments from CSL The U.S. has reportedly awarded $72M to GSK (NYSE:GSK), Sanofi (NASDAQ:SNY), and CSL (OTCQX:CSLLY) to expand the production of bird flu vaccines amid an ongoing outbreak among poultry and livestock that has led to fears of a potential human-to-human transmission of the virus.

The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of bird flu vaccines.

US has announced team up with multinational pharmaceutical companies CSL, GSK, Sanofi, and Seqirus for a $72 million worth of bird flu vaccine production initiative.On Friday, October 4, the US Federal health officials announced that they will

Australia's CSL said on Wednesday it has got a contract from the U.S. Department of Health and Human Services (HHS) worth $121.4 million to increase the U.S. government's stockpile for bird flu vaccines to 40 million doses.

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. | CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.